TrialA Study of JADE101 in Participants With Immunoglobulin A Nephropathy
Trial details
- Registry ID
- NCT07541287
- Phase
- Phase 2
JBIO
Jade Biosciences, Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
1Trials in this database
2Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of JADE101 in Participants With Immunoglobulin A NephropathyNCT07541287 | JBIO | Phase 2 | Recruiting | 2029-01Estimated |
Latest recorded trial changes
A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
NCT07541287 · Jade Biosciences, Inc.
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Safety and tolerability of JADE101 in participants with IgA nephropathy
+ After
Measure: Incidence of treatment-emergent adverse events (safety and tolerability)
Recruitment status changed
− Before
Not yet recruiting
+ After
Recruiting